[1] Binnewies M, Roberts EW, Kersten K, et al.Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24(5): 541-550. [2] Wu J, Waxman DJ.Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy[J]. Cancer Lett, 2018, 419: 210-221. [3] Zhao J, Wang SZ, Tang X, et al.Analysis of thermochemotherapy-induced apoptosis and the protein expressions of Bcl-2 and Bax in maxillofacial squamous cell carcinomas[J]. Med Oncol, 2011, 28(Suppl 1): 354-359. [4] 李鼎九. 肿瘤热疗学 [M]. 郑州: 郑州大学出版社, 2003: 1-506. [5] Wang H, Zhang L, Shi Y, et al.Abscopal antitumor immune effects of magnet-mediated hyperthermia at a high therapeutic temperature on Walker-256 carcinosarcomas in rats[J]. Oncol Lett, 2014, 7(3): 764-770. [6] Lasalvia-Prisco E, Goldschmidt P, Galmarini F, et al.Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies[J]. Med Oncol, 2012, 29(5): 3626-3633. [7] Ellebaek E, Engell-Noerregaard L, Iversen TZ, et al.Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase Ⅱ trial[J]. Cancer Immunol Immunother, 2012, 61(10): 1791-1804. [8] Aoto K, Mimura K, Okayama H, et al.Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma[J]. Oncol Rep, 2018, 39(1): 151-159. [9] Emens LA, Asquith JM, Leatherman JM, et al.Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation[J]. J Clin Oncol, 2009, 27(35): 5911-5918. [10] Galluzzi L, Senovilla L, Vitale I, et al.Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883. [11] Chen P, Liu B, Hu M.The effect of hydroxycamptothecin and pingyangmycin on human squamous cell carcinoma of the tongue[J]. Oncol Lett, 2013, 5(3): 947-952. [12] Zerbini A, Pilli M, Penna A, et al.Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses[J]. Cancer Res, 2006, 66(2): 1139-1146. [13] Ito A, Honda H, Kobayashi T.Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression[J]. CanceR Immunol Immunother, 2006, 55(3): 320-328. [14] Adkins I, Sadilkova L, Hradilova N, et al.Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells[J]. Oncoimmunology, 2017, 6(5): e1311433. [15] Mahmoudi K, Bouras A, Bozec D, et al.Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy, and application in humans[J]. Int J Hyperthermia, 2018, 34(8): 1316-1328. [16] Ahmed K, Tabuchi Y, Kondo T.Hyperthermia: an effective strategy to induce apoptosis in cancer cells[J]. Apoptosis, 2015, 20(11): 1411-1419. |